Cargando…
Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia
Quantification of BCR-ABL1 mRNA levels in peripheral blood of chronic myeloid leukemia patients is a strong indicator of response to tyrosine-kinase inhibitors (TKI) treatment. However, additional prognostic markers are needed in order to better classify patients. The hypothesis of leukemic stem cel...
Autores principales: | Ruiz, María Sol, Sanchez, María Belén, Gutiérrez, Leandro, Koile, Daniel, Yankilevich, Patricio, Mosqueira, Celeste, Cranco, Santiago, Custidiano, María del Rosario, Freitas, Josefina, Foncuberta, Cecilia, Moiraghi, Beatriz, Pavlovsky, Carolina, Pérez, Mariel Ana, Ventriglia, Verónica, Ávalos, Julio Sanchez, Mordoh, José, Larripa, Irene, Bianchini, Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945542/ https://www.ncbi.nlm.nih.gov/pubmed/29755649 http://dx.doi.org/10.18632/oncotarget.24749 |
Ejemplares similares
-
miRNome profiling of LSC-enriched CD34(+)CD38(−)CD26(+) fraction in Ph(+) CML-CP samples from Argentinean patients: a potential new pharmacogenomic tool
por: Ruiz, María Sol, et al.
Publicado: (2021) -
In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy
por: Sanchez, María Belén, et al.
Publicado: (2023) -
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal
por: Pavlovsky, Carolina, et al.
Publicado: (2023) -
Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report
por: Aris, Mariana, et al.
Publicado: (2018) -
P041: Low percentage of T lymphocytes in Hodgkin’s Lymphoma lymph nodes, measured by flow cytometry, is associated with inferior progression free survival regardless of negative interim pet scan status
por: Korin, Laura, et al.
Publicado: (2022)